IMAB

I-Mab

1 day chart

About IMAB

I-Mab is a China-based company mainly engaged in the development of innovative global biotechnology. The Company's main businesses include engaging in track record in innovation, developing innovative drug candidates and conduct clinical validation of the assets and commercialization. The Company's pipeline is composed of ten clinical-stage assets and ten preclinical assets, among which seven assets have moved to Phase 2 or Phase 3 clinical trial stage. Its pipeline is expected to yield three near-term NDA filings and/or product launches, including felzartamab for multiple myeloma (MM), eftansomatropin alfa for pediatric growth hormone deficiency (PGHD), and potentially lemzoparlimab for myelodysplastic syndromes (MDS) and later for acute myeloid leukemia (AML) and non-Hodgkin's lymphoma (NHL).

Buy US stocks in Australia starting with IMAB. Open an account and start investing today!

Market Capitalisation

$260.93M

Price-earnings ratio

Dividend yield

0.00%

Volume

8.8K

High today

$3.18

Low today

$3.12

Open price

$3.13

52-week high

$21.44

52-week low

$2.73

IMAB FAQs

How much is one share of I-Mab?

One share of I-Mab is valued at $3.22.

What is the ticker symbol for I-Mab?

The ticker symbol for I-Mab is IMAB.

How do I buy IMAB shares in Australia?

To buy IMAB stocks in Australia you'll need to open an account with a broker like Stake.
To do so follow these steps:

Sign up in minutes, all you need is some I.D.
Choose Stake Wall St
Deposit directly into your Stake wallet and you're ready to invest in IMAB

What is the 52-week high for I-Mab stock?

The I-Mab 52-week high stock price is $21.44.

What is the 52-week low for I-Mab stock?

The I-Mab 52-week low stock price is $2.73.

What is the market capitalisation of I-Mab IMAB?

As of 29/03/2023 I-Mab has a market cap of $261M.

Related Stocks

This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.